Page 91 - Hospital Authority Convention 2017

Masterclasses

M1.3 Diabetic Eye Disease: What’s New? 10:45 Room 221

Prevention of Diabetes Mellitus Retinopathy: Glycaemic Control and Beyond
Choi CH
Department of Medicine, Queen Elizabeth Hospital, Hong Kong HOSPITAL AUTHORITY CONVENTION 2017
One important target of diabetes (DM) management is the prevention of diabetes retinopathy (DMR), which is quite common
in those with prolonged disease and poor glycaemic control, and can be potentially leading to blindness. Numerous studies
confirmed that good glycaemic control can prevent the development or retard the progression of DMR, both in type 1 and
type 2 DM patients. More recent studies also revealed that other factors like appropriate blood pressure and lipid control may
also be equally important in preventing DMR. Moreover different new classes of hypoglycaemic agents like glycogen-like
peptide-1 agonist (GLP-1A) and sodium-glucose co-transporter-2 inhibitor (SGLT-2I) and bariatric surgery may have different
specific effects, whether good or bad, on DMR. In future, hopefully we can find out the missing link between DM and DMR,
through the understanding of genomic variations, epigenetic transcriptome, metabolome and microbiomes fingerprinting, so
that we can provide personalised care to patients.

M1.4 Diabetic Eye Disease: What’s New? 10:45 Room 221 Tuesday, 16 May

Latest Evidence Basis for Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Brelen M
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong

The prevalence of diabetes continues to rise globally and it is now estimated that more than 4 million adults have diabetic
retinopathy (DR). As ophthalmologists, we are becoming increasingly challenged in the screening and management of
diabetic eye disease. Recently anti-Vascular Endothelial Growth Factors (anti-VEGFs) have revolutionised our management
of patients with DR and diabetic macular edema (DME). However, there are still many challenges remained. We are still
faced with the difficulty of early detection and prompt treatment of patients with potential sight-threatening retinopathy.
The currently available treatments are both costly and have a heavy treatment burden on patients and caregivers. Finally,
a substantial proportion of patients is failing treatments despite maximal medical therapy. There are therefore continuous
improvements in the management of patients as well as novel therapies becoming available. This presentation will aim
to summarise the most recent advances in these areas. The recent published and ongoing clinical trials in DR and DME
management will be summarised. The learning objectives for audiences are to appreciate the challenges that still remain in
the management of DR and DME and what new treatment options are now available.

89